Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab
Choon Guan Chua, Gin Tsen Chai, Xin Rong Lim, Mona Manghani, Bernard P. Leung, Li Wearn Koh
Abstract
<p dir="ltr">Anti-melanoma differentiation-associated 5 gene autoantibody (anti-MDA5 Ab) positive dermatomyositis (DM) with rapidly progressive interstitial lung disease (RP-ILD) is a severe and difficult-to-treat form of autoimmune myositis with unfavourable 6-month survival rates. We report a case of refractory anti-MDA5 DM RP-ILD that improved after daratumumab, a human monoclonal antibody targeting CD38-positive plasma cells.</p>
Topics & Concepts
MedicineDaratumumabInterstitial lung diseaseAutoantibodyDermatomyositisRefractory (planetary science)MDA5LungInternal medicinePathologyGastroenterologyDermatologyImmunologyAntibodyMonoclonal antibodyRNA interferenceRNAPhysicsGeneChemistryBiochemistryAstrobiologyInflammatory Myopathies and DermatomyositisSkin Diseases and DiabetesImmunodeficiency and Autoimmune Disorders